These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 34762160)
1. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma. Jenseit A; Camgöz A; Pfister SM; Kool M Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160 [TBL] [Abstract][Full Text] [Related]
2. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826 [TBL] [Abstract][Full Text] [Related]
3. EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations. Nambirajan A; Sharma A; Rajeshwari M; Boorgula MT; Doddamani R; Garg A; Suri V; Sarkar C; Sharma MC Brain Tumor Pathol; 2021 Jan; 38(1):30-40. PubMed ID: 33130928 [TBL] [Abstract][Full Text] [Related]
16. Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma. Pratt D; Quezado M; Abdullaev Z; Hawes D; Yang F; Garton HJL; Judkins AR; Mody R; Chinnaiyan A; Aldape K; Koschmann C; Venneti S Acta Neuropathol Commun; 2020 Mar; 8(1):37. PubMed ID: 32197665 [No Abstract] [Full Text] [Related]
17. Molecular subtyping of ependymoma and prognostic impact of Ki-67. Lim KY; Lee K; Shim Y; Park JW; Kim H; Kang J; Won JK; Kim SK; Phi JH; Park CK; Chung CK; Yun H; Park SH Brain Tumor Pathol; 2022 Jan; 39(1):1-13. PubMed ID: 34812989 [TBL] [Abstract][Full Text] [Related]
18. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821 [TBL] [Abstract][Full Text] [Related]
19. Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups. Łastowska M; Matyja E; Sobocińska A; Wojtaś B; Niemira M; Szałkowska A; Krętowski A; Karkucińska-Więckowska A; Kaleta M; Ejmont M; Tarasińska M; Perek-Polnik M; Dembowska-Bagińska B; Pronicki M; Grajkowska W; Trubicka J J Pathol Clin Res; 2021 Nov; 7(6):565-576. PubMed ID: 34314101 [TBL] [Abstract][Full Text] [Related]
20. EZHIP is a specific diagnostic biomarker for posterior fossa ependymomas, group PFA and diffuse midline gliomas H3-WT with EZHIP overexpression. Antin C; Tauziède-Espariat A; Debily MA; Castel D; Grill J; Pagès M; Ayrault O; Chrétien F; Gareton A; Andreiuolo F; Lechapt E; Varlet P Acta Neuropathol Commun; 2020 Nov; 8(1):183. PubMed ID: 33153494 [No Abstract] [Full Text] [Related] [Next] [New Search]